EU to strengthen ethical assessment of trial data in drug approval dossiers
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies submitting new European drug approval applications involving data from clinical trials conducted outside the EU can expect to have this data more closely scrutinised for conformity to ethical and GCP standards under new guidance that comes into force next month.